For example, antibodies directed against specific tumor fusion proteins or chimeric antigen receptor T cells (CAR T cells) provide specific and active immunity against specific cell types or tumor neoantigens, or checkpoint blockade inhibitors such as anti-PD-1/PD-L1 or anti-CTLA4 increase the overall activity of T cell responses, increase antitumor immunity (32). Here, CTLA4 is linked to neoplasm.